MiNK Therapeutics is making waves in the cell therapy landscape with its groundbreaking allogeneic invariant natural killer T ...
ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 ...
Dr. Jennifer Buell (President, CEO & Director) reiterated MiNK’s differentiation as “an off the shelf” allogeneic iNKT platform that is “administered without lymphodepletion, without HLA matching,” ...
MiNK Therapeutics (NASDAQ:INKT) outlined progress across its allogeneic invariant natural killer T-cell (iNKT) platform ...
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential NEW YORK, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results